All Industries

Mariner Acquires Woodbridge International, Enhances M&A Advisory Capabilities

Mariner

Mariner, a national wealth advisory firm, today announced its acquisition of New Haven, Conn.-based Woodbridge International, a leading middle-market mergers and acquisitions firm. This acquisition significantly bolsters Mariner’s position as a comprehensive financial advisory firm, deepening its expertise in sell-side M&A advisory services. Woodbridge, which is known for its innovative approach to sell-side M&A transactions and its extensive experience across a wide range of industries, brings over 30 years of expertise and a team of seasoned professionals to Mariner. The acquisition will enable Mariner to offer enhanced M&A advisory services to its clients, leveraging Woodbridge’s global reach and industry-specific knowledge. “The integration of Woodbridge International into the Mariner family marks a transformative step in our mission to deliver comprehensive, client-focused financial services,” said Marty Bicknell, CEO and president of Mariner. “Woodbridge’s impressive history of successful transactions and its commitment to client-centric solutions align seamlessly with our core values. This acquisition enables us to broaden our service offerings, empowering our clients to navigate the complexities of M&A with greater confidence and precision.” Woodbridge has built a reputation for delivering exceptional results for its clients, focusing on maximizing value through innovative marketing strategies and a deep understanding of market dynamics. With offices in New Haven, CT and Cape Town, South Africa, Woodbridge is equipped with a global database of 8,400 private equity groups and 410,000 strategic companies. Woodbridge casts one of the widest nets in the industry, quickly identifying the greatest number of buyers. "For our team, joining forces with Mariner opens up incredible avenues for growth," said Robert Koenig, CEO of Woodbridge International. "We now have a clear path to potentially double our business within the next few years. By expanding our offerings, we can cultivate idle leads and provide more value to clients than ever before. This is an exciting time for Woodbridge, especially as we aim to capture the anticipated wave of baby boomer business exits." Both Mariner and Woodbridge are united by a shared commitment to making a meaningful impact on the clients they serve. This cultural alignment is at the heart of the acquisition, enabling Mariner to enhance its service offerings at a time when 35% of financial advisors are expected to retire over the next decade and $17 trillion in small businesses are projected to be sold in the next 20 years. This acquisition strengthens Mariner’s ability to support its 1,200 business owner clients, particularly during key business transitions. The acquisition was finalized on August 30, 2024, and the integration of Woodbridge’s team and operations into Mariner’s existing structure is expected to be completed by the end of the year. Woodbridge International will maintain its current offices and continue to operate under its established brand for a period of time, ensuring continuity for its clients and employees. To learn more, visit Mariner.com. Mariner is a privately held, national financial services firm equipped with the expertise to help meet the wealth needs of our clients. Our advisors have access to in-house professionals covering everything from tax, estate, trust and insurance to investment banking and valuation, so they can maximize time spent creating unified wealth plans with clients. By opening more windows of wealth, we create opportunities to positively impact the lives of many. With this purpose, we intend to raise the bar for the entire industry. Founded in 2006 with $300 million in assets under advisement, Mariner and its affiliates now advise on over $245 billion in assets as of 6/30/24. Contact Details Remi Yuter mariner@hotpaperlantern.com Company Website https://www.mariner.com/

September 03, 2024 09:00 AM Eastern Daylight Time

Image

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Benzinga

By Johnny Rice, Benzinga Bill Caragol, CFO of Mainz BioMed (NASDAQ: MYNZ), was recently a guest on Benzinga’s All-Access. Mainz BioMed, maker of clinical laboratory tests, says it is committed to saving lives and reducing healthcare costs through early disease detection and prevention. For cancer and chronic conditions, patients can now live longer, healthier lives thanks to advances in diagnostic technology. Genetic and genomic tests are at the forefront of this progress. By revealing patients' unique genetic profiles, these tests can allow doctors to tailor treatments more effectively, ushering in an era of personalized medicine. Caragol spoke about promising data from recent trials. Watch the full interview here: Featured photo by National Cancer Institute on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 09:00 AM Eastern Daylight Time

Video Image

How Dunamis Charge Is Helping Shape The Future Of EV Charging Infrastructure Through Its Wide Range Of American-Made High-Tech Solutions

Benzinga

By Meg Flippin, Benzinga Image: Dunamis Charge Level 2 EV Residential Charger In the rapidly evolving landscape of electric vehicles (EVs), Dunamis Charge aims to stand out as an innovator. As the EV market takes off, projected to reach $1.6 trillion by 2034, Dunamis Charge wants to be at the forefront of the charging infrastructure revolution with its charging solutions. After all, for the EV market to take off, there must be a level playing field where everyone can own an EV regardless of where they live or how much money they have. For that to happen, there needs to be robust, affordable and easy-to-use charging infrastructure that’s accessible everywhere. That’s what Dunamis offers. Cutting-Edge Technology And American Innovation Dunamis Charge's EV charging stations are engineered to exceed expectations in three critical areas: reliability, durability and charging speed. The company says its intelligent charging technology ensures consistent performance, minimizing downtime and maximizing user satisfaction. Using high-quality, weather-resistant materials, these chargers are built to last, and designed to withstand harsh environmental conditions, from extreme temperatures to severe weather events. Speed is of the essence in today's fast-paced world, and Dunamis Charge delivers. Their chargers range from 9kW to over 360kW, catering to various charging needs. This means EV owners can charge their vehicles in minutes rather than hours, potentially revolutionizing the convenience of electric vehicle ownership. Dunamis Charge’s manufacturing facility is in Detroit, a part of its commitment to offering American-made products. With the capacity to produce 200,000 EV chargers annually on a single shift, Dunamis seems well-positioned to help meet the growing demand for charging infrastructure across the United States. This strategic location not only supports local jobs but also ensures the highest quality standards in production, reports Dunamis. Scalability, Adaptability And Environmental Impact Recognizing the diverse needs of the EV market, Dunamis Charge offers a range of solutions to meet varying charging requirements across different vehicles, locations and use cases. From Level 2 AC chargers to high-power DC fast chargers, the company provides a comprehensive suite of charging solutions suitable for residential areas, commercial parking lots, multi-family dwellings and public spaces. Dunamis Charge's intelligent charging systems incorporate advanced features such as load balancing and smart energy management. These technologies optimize charging efficiency, reduce strain on the electrical grid, and lower operational costs for charging station operators. The company's commitment to upgradeable infrastructure ensures that its charging stations can evolve with rapidly advancing EV technology. Beyond providing cutting-edge technology, Dunamis Charge is helping drive sustainable change in the transportation sector. By facilitating the widespread adoption of electric vehicles, the company plays a crucial role in reducing carbon emissions. Their energy-efficient charging solutions and sustainable manufacturing practices align with a broader mission of promoting a greener future. Helping Shape The Future Of EV Charging Dunamis Charge is actively helping shape the future of electric vehicle infrastructure. The company reports being at the forefront of developing ultra-fast charging solutions, aiming to push the boundaries of charging speeds to make EV charging as quick and convenient as refueling a traditional gasoline vehicle. Looking ahead, Dunamis Charge envisions seamless integration with smart grids, enabling dynamic load management and vehicle-to-grid capabilities. The company is also exploring wireless charging technology, which could revolutionize EV charging by making it even more convenient and opening up new possibilities for infrastructure deployment. Investment Opportunity in Advanced EV Charging Technology As the EV charging station market is forecast to grow at a CAGR of 36% over 2022-2032, Dunamis Charge is all in. The company's focus on reliability, durability and speed, combined with its strategic positioning and scalable business model, sets it apart, and the company may be worth looking into for investors looking for opportunities in this growing market. As the world moves towards a more sustainable future, Dunamis Charge may be poised to play a crucial role in powering that transition. To learn more about this investment opportunity and how Dunamis Charge is shaping the future of EV charging, click here. Featured photo courtesy of Dunamis Charge. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:50 AM Eastern Daylight Time

Image

Revolutionizing Trading: BullRush’s Plan To Change The Game

Benzinga

By James Blacker, Benzinga Traders eager to sharpen their skills now have the chance to do so while competing for cash prizes with a new trading platform that blends the excitement of fantasy sports with trading. With its gamified, interactive environment offering multi-asset trading competitions, trivia tournaments and other challenges, BullRush is changing the game for traders of all levels. Launched in beta on July 10, the platform has already attracted over 13,700 traders from more than 150 countries. Those participating in this testing phase can contribute to the platform’s development by exploring BullRush’s cutting-edge features, which include live market simulation, advanced strategy testing and interactive dashboards that let you monitor your performance, track rankings and analyze your competitors. Even during the beta phase, testers can win real prizes in competitions, as well as earn XP and climb the leaderboard. Participants will also be able to talk with other traders through the BullRush Discord channel, sharing strategies and getting feedback. BullRush plans to release an in-platform chat in the future to make communication even easier. The full version, which launches on September 9, will include daily, weekly and monthly trading competitions in asset classes like forex, crypto, futures and CFDs. Some of these will be free to take part in, while others will require an entry fee, with prizes depending on the entry fee and the number of participants. It will also offer free-to-enter trivia competitions, where traders can win cash prizes and XP, as well as trading challenges that give them a chance to win double the entry fee. To help traders hone their skills, the company also plans to launch BullRush Academy, which will be available to all BullRush traders. This will include a library of trading courses and videos, as well as expert trade analysis of your past trades. Traders will also have the opportunity to fine-tune their strategy in practice arenas and free-to-enter trading games. Trade, Compete, Win Trading competitions are not exactly new, with some prop firms and brokers running their own versions of them, so what makes BullRush different? The primary concern many have with most trading games is that they are single-round contests with limited rules, where the winner is the trader with the highest percentage return. What this means is that anyone could catch a lucky trade and get a huge return that wins them the game. To ensure that only the best traders win, BullRush has developed multi-round tournaments, similar to the format used in sporting events such as sports World Cups or the Olympics. In BullRush tournaments, traders progress through anywhere from 2 to 12 rounds until a winner emerges. For example, in the first BullRush competition held in July, a total of 5,246 participants were divided into four groups for the first round. After a week of trading, the top 25 traders from each group advanced to the Championship Round, where the top 100 traders competed to be crowned the first BullRush Tournament Champion. To help promote the official launch of Bullrush on September 9, the company is running a multi-asset trading competition where 100 traders will share a total prize pool of $10,000. If you think you’ve got what it takes to take home the prize, you can sign up for it here. Whether you trade FX, indices, metals or crypto, BullRush offers an excellent environment to test strategies, learn from others and enjoy the thrill of a gamified trading competition. Featured photo courtesy of BullRush. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:45 AM Eastern Daylight Time

Image

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Benzinga

By Anthony Termini, Benzinga In August 2020, popular actor Chadwick Boseman succumbed to colorectal cancer at the age of 43 after a four-year battle with colon cancer. The untimely death of the Black Panther star saw many fans overcome with grief but also brought attention to the danger posed by such cancers. Colorectal cancer is the second leading cause of cancer death in the United States, with more than 100,000 cases diagnosed so far in 2024. Mainz Biomed (NASDAQ: MYNZ), a German company whose U.S. offices are in Berkeley, California, believes the threat can be mitigated by technology and is working on a predictive test that may be more effective than solutions currently on the market. Benzinga recently sat down with the company’s CFO, Bill Caragol, to discuss the challenge and all the work the company is doing to help address it. The Available Options For Detecting Colorectal Cancer The standard of care for detecting colorectal cancer has since 1969 been the colonoscopy. The procedure is invasive and not very pleasant. In 2014, the fecal immunochemical test (FIT) received FDA approval. The test analyzes a person’s DNA to detect advanced adenomas, the pre-cancerous polyps that “may be the most valid…marker for present and future colorectal cancer risk,” according to research published by the National Library of Medicine. Blood-based tests are also available to detect colorectal cancer risk. However, some in the medical community are cautious about their use. According to David Lieberman, MD, chair of the American Gastroenterological Association’s Colorectal Cancer Workshop, “blood tests are neither as effective or cost-effective" as established colorectal cancer screening tests – something that Mainz’s Caragol testifies to, as well, stating that doctors continue to prescribe stool-based tests over blood tests because of the clinical differentiation since stool-based tests are better at detecting early-stage cancer, despite the “yucky factor.” He added,”Remember, [with] colorectal cancer – you detect late-stage, there’s a roughly 10% survival. When you catch it in early-stage, there’s 90% survival.” Mainz’s Breakthrough Device Leads To Next-Generation Screening Test Mainz has developed a molecular diagnostic solution to detect colon cancer risk. In July, Mainz submitted an application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for a non-invasive colorectal cancer product that includes a portfolio of mRNA biomarkers. Studies conducted by Mainz revealed that its mRNA-powered test showed a sensitivity for detecting precancerous polyps that is double that of products currently on the market. In those studies, competitors’ tests “demonstrated efficacy of detecting advanced adenomas in the 40% range,” says Bill Caragol. Caragol added that readouts from the three clinical studies Mainz conducted between 2023 and 2024, “demonstrated consistent accuracy above 80%, a quantum leap...over the other stool-based tests.” Mainz says its flagship product, ColoAlert®, misses far fewer cases than its competitors’ tests. Mainz puts the number at up to 60% fewer cases. Its next-generation FIT test is an enhancement of ColoAlert and was submitted to the FDA in July for Breakthrough Device designation. The next-generation FIT test is complemented by a proprietary algorithm that uses artificial intelligence and machine learning to identify mRNA biomarkers in order to better detect the early warning signals of potential colorectal cancer. Mainz said the test is “a new gold standard for noninvasive detection of advanced adenomas.” The company is scheduled to conduct an FDA pre-market approval study in 2025 for its next-generation test. A focus of the study is to distribute the next-generation test kit through the currently existing network of FDA-approved national reference testing laboratories in the United States. This differs from other products currently on the market in that the companies that make those test kits also control the testing process. As Caragol describes it, “every test [is] manufactured by them, sent out by them, returned to them [for analysis], test results delivered.” As a result, says Caragol, Mainz will have “the only product that will fit into the largest distribution.” Milestones Mainz Is Focused On For The Year Ahead Mainz has a clear strategy for approaching the market. Caragol said that they realize that as a small company targeting a large market, they will have to strategically align themselves with larger companies. The company is looking to partner with a PCR provider as well as one of the national reference labs. PCR labs specialize in blood, urine and other molecular testing to detect pathogens, commonly used for diagnosing infections like COVID-19. National reference labs offer a wide range of high-accuracy diagnostic services, including PCR, serving as centralized hubs for specialized testing across various locations. Having these partnerships in place is necessary for Mainz to conduct its FDA pre-market approval study. Importantly, they will also be important allies if the company receives approval to sell the kits. They will be integral components of Mainz’s commercial go-to-market strategy. At that point, Mainz’s commercial roadmap will focus on creating partnerships and awareness within physician networks and health care professionals about the differentiating benefits of the ColoAlert mRNA powered test. Investment Drivers For Companies Like Mainz Biomed If the company can meet each of its milestones, then it could set a course for future growth. The U.S. market for colorectal screening “is over $30 billion a year,” according to Caragol. He notes that the market is double that worldwide. There are a number of companies competing domestically for colorectal screening, the most notable of which is Exact Sciences Corp. (NASDAQ: EXAS). Caragol says Exact has about a 10% share of U.S. sales. As such, there may be an opportunity for Mainz if its next-generation test receives FDA approval in the next few years. The company says that a successful launch could open the door to other products, including test kits for pancreatic and other gastrointestinal cancers – significantly expanding its addressable market. For more information about Mainz Biomed listen to the conversation Bill Caragol had with Benzinga’s Zunaid Suleman. Featured photo by Furiosa-L from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:35 AM Eastern Daylight Time

Image

AJNA BioSciences’ Strategy For Market Leadership In Botanical Drug Development With Magic Mushrooms And Cannabis

Benzinga

By Anthony Termini, Benzinga Individual investors can own equity in AJNA BioSciences on the same terms as venture capitalists and professional angels. Click here for details. Consumers are increasingly demanding natural health solutions, with recent surveys demonstrating that a majority of consumers believe products with natural ingredients are healthier and that botanical supplements are effective. Many people believe that “food should be medicine.” Littleton, Colorado-based AJNA Biosciences says it is aiming to build a bridge “between what people want, and physician advocacy they can trust.” AJNA's Pharmaceuticals Come From Nature Backed By Science AJNA is focused on developing a new class of drugs derived from botanicals. The company is exploring plant and fungi species with therapeutic compounds that address specific conditions. “The future of medicine is actually millions of years old,” says Joel Stanley, CEO of AJNA. This ethos is guiding AJNA’s development of two drug candidates focused on treating conditions that it estimates today affect more than 80 million people. The company’s research team, led by scientists from Harvard, Johns Hopkins and New York University, are working on botanical drugs to treat or support people with Autism Spectrum Disorder and Generalized Anxiety Disorder. Today, there is no FDA-approved natural remedy for either of these conditions, reports AJNA. They can both be treated with synthetic compounds engineered by big pharmaceutical companies, but those drugs can come with a number of unpleasant side effects. AJNA distinguishes itself by participating in the evolving field of botanical drug development and is pioneering a new regulatory pathway to produce drugs from plant medicine that are ultimately approved by the U.S. Food and Drug Administration (FDA). AJNA has advanced the development of two prescription drug candidates by standardizing botanical raw materials to meet strict FDA guidelines. The first drug candidate, CBD for Autism Spectrum Disorder (ASD), is preparing to enter phase 2 clinical trials with an upcoming Investigational New Drug (IND) filing, while the second candidate, Psilocybin for Generalized Anxiety Disorder (GAD), is approaching phase 1. The two drugs in development are a full-spectrum cannabis-derived drug and a psilocybin-based antidepressant. AJNA says it will look to expand indications for these products beyond autism and anxiety to also include post-traumatic stress disorder, various sleep disorders, attention-deficit/hyperactivity disorder and chronic pain. A Holistic Approach Based On Ethics And Sustainability AJNA believes it is tapping into rising consumer demand for holistic treatment options that include natural remedies. The company says that demand has never been higher. As part of the company’s ethos, it is committed to sustainable methods in its research and development processes. It is also committed to reducing its ecological footprint. AJNA follows Stanley's previous venture, a company he founded with his brothers called Charlotte’s Web Holdings (OTC: CWBHF). It started out as a mission not a company, giving away an extract to those who could benefit, then gained public recognition after the CBD oil was being used to treat seizures in 5-year-old Charlotte Figi. The company prioritizes minimizing the use of unnecessary and potentially harmful chemicals. AJNA's psilocybin drug is processed using only the water from the fungi itself, without any added agents or artificial chemicals. If this drug gains FDA approval, it could be one of the few organic options available on the market. Additionally, the company's commitment to environmental sustainability results in a largely organic waste stream, which is repurposed as compost and used as a soil amendment throughout the Denver area. AJNA Could Be Poised To Benefit From Significant Shifts In Perception The demand for psychedelic-assisted therapy is increasing at a time when the FDA is defining new drug development pathways for botanical drugs to get approved. This is helping AJNA build a bridge between what people want and the physician advocacy necessary to gain wider public trust. The company’s Chief Medical Advisor, Orrin Devinsky, is one of the first clinicians to research cannabinoids. His work as principal investigator led to the development of Epidiolex, the only FDA-approved cannabis-derived drug currently on the market. “It is important for us to provide a [botanical] option that has clinical science behind it, so doctors can get behind it, so insurance can cover it for people in the future,” said Stanley about AJNA’s research and development and pending clinical trials. AJNA also gains an advantage from unique intellectual property regulations that protect botanical drugs. Plant variety patents provide 20 years of protection, significantly longer than the five to seven years typically granted to synthetic drug compounds. Big Pharma May Look To Botanicals For Future Growth AJNA believes that major pharmaceutical and biotechnology companies will increasingly recognize the therapeutic and commercial potential of botanical drugs. Cannabinoids and psychedelics could be part of future opportunities for large players to acquire or merge with smaller botanical drug companies. This is part of an established playbook in the biotech industry. A small company’s successful drug development platform creates potential liquidity for investors. This may include the acquisition of a single drug candidate or the entire company. In many cases, these acquisitions take place before the target company begins to generate revenue. In AJNA’s case, the company is working with Wefunder to help it raise capital. Wefunder is a public benefit corporation with a goal to “fix capitalism” in addition to helping companies create shareholder value. More information is available on the Wefunder website. Featured photo courtesy of AJNA BioSciences. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:30 AM Eastern Daylight Time

Image

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

News Release

Strong Management and Partners Make Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) a Compelling Opportunity

Railtown AI

Artificial intelligence has rapidly evolved from a futuristic concept to a central component of modern business strategy. With the AI market projected to surge from $196.63 billion in 2023 to transformative levels by 2030, businesses across all sectors are leveraging AI to boost efficiency, cut costs, and secure a competitive advantage. From automating complex tasks to enhancing customer interactions, AI is revolutionizing industries. As the AI sector expands, investors are increasingly turning their attention to companies driving this innovation. One standout example is Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF), a company poised to make significant waves in the industry. Railtown AI Technologies Inc. is emerging as a standout player in the artificial intelligence landscape, driven by its robust management team and strategic partnerships. The company's focus on AI solutions, particularly through its innovative Conductor AI platform, underscores its potential to transform various sectors. Core Technology and Offerings Railtown's cloud-based Application General Intelligence Platform stands out for its flexibility, supporting both cloud and on-premise deployments. It uses machine learning to adapt from connected applications, which enhances decision-making and reduces operational costs. The platform’s real-time processing capabilities are crucial for efficient software development. Key Features Root Cause Analyzer: Identifies and prioritizes errors, saving developers over eight hours a week and reducing maintenance costs. Conductor AI Assistant: Provides instant, natural language responses to development queries and continuously improves based on user feedback. Velocity Dashboard: Tracks performance metrics, aiding management in planning and resource allocation. Release Notes Automator: Generates clear release notes in under two minutes, ensuring consistency and saving time. Ticket Generator: Uses AI to streamline ticket creation, minimizing manual input and allowing more focus on coding. API No-Code Virtual Developer: Enables users to create new functionalities without coding skills, democratizing development and boosting productivity. Strategic Partnerships Railtown AI Technologies Inc.’s partnerships play a crucial role in amplifying its technological capabilities and market reach. In July 2024, RALIF secured a strategic alliance with Mila, the Quebec Artificial Intelligence Institute, under the leadership of Professor Yoshua Bengio. This partnership provides Railtown with access to Mila’s cutting-edge research and a network of AI experts. It allows Railtown to integrate the latest advancements in deep learning into its Conductor AI platform, further enhancing its technological prowess. Mila’s involvement also aids in talent acquisition and training, ensuring that Railtown remains at the forefront of AI innovation. Similarly, Railtown AI's collaboration with the Alberta Machine Intelligence Institute (Amii), announced in July 2024, is instrumental in advancing its capabilities. Amii’s expertise in reinforcement learning and natural language processing complements Railtown’s technology, contributing to the refinement of its AI solutions. This partnership brings additional expertise and resources to Railtown, accelerating the development of sophisticated AI applications. Furthermore, Railtown retains ownership of all intellectual property developed through this collaboration, which strengthens its competitive position in the market. The company's earlier partnership with Quisitive Technology Solutions Inc. highlights its commitment to practical applications of AI. This integration incorporates Railtown’s AI technology into Quisitive’s Velocity Insights toolset, enhancing software engineering productivity and project management. This partnership showcases Railtown’s ability to apply its technology effectively in real-world scenarios, expanding its influence within enterprise environments. Leadership Driving Innovation Railtown AI’s leadership team is a key asset, guiding the company through its growth and innovation journey. Cory Brandolini, Founder and CEO, brings over 30 years of experience in technology and software ventures. His background includes raising significant capital for technology companies and leading successful exits, such as the acquisition of Teleo Inc. by Microsoft. Brandolini’s strategic vision and industry connections are vital for steering Railtown AI towards its ambitious goals. Co-Founder and CTO Marwan Haddad contributes over 25 years of experience in software development, having led engineering teams at major tech platforms like RESAAS and Fortune 500 companies. Haddad’s technical expertise ensures that Railtown’s AI solutions are developed and executed to the highest standards. Dr. Elliot Holtham, Co-Founder and AI Data Scientist, brings extensive experience in machine learning and data science. His previous role at Xtract AI, acquired by Patriot One Technologies, and his academic achievements bolster Railtown’s R&D efforts and drive innovation within its technology offerings. Kevin O’Neil, Advisory Chair, offers a wealth of experience in technology investing and advisory roles. His previous role as CEO of Xtract AI and his expertise in strategic guidance and investment reinforce Railtown’s market strategy and growth trajectory. Conclusion Railtown AI Technologies Inc. represents an intriguing investment opportunity, distinguished by its innovative Conductor AI platform, strategic partnerships, and a seasoned leadership team. The collaborations with Mila and Amii enhance Railtown’s technological capabilities and research potential, while the partnership with Quisitive illustrates the practical application of its AI solutions. With a management team renowned for its expertise and a clear focus on delivering advanced AI technologies, Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) could be a stock to watch for continued success in the evolving artificial intelligence sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

September 03, 2024 06:00 AM Eastern Daylight Time

Aligning Investment Strategies through the Health Care Select Sector SPDR Fund (XLV)

Select Sector SPDR

In the evolving landscape of healthcare, the Health Care Select Sector SPDR Fund (XLV) stands as an investment vehicle for those looking to diversify their portfolio within the U.S. healthcare sector. By tracking healthcare stocks within the S&P 500 Index, XLV offers broad exposure to foundational companies that are central to healthcare in America. Featuring a blend of leading entities across various sub-sectors, XLV's holdings provide investors with exposure to many of the healthcare sector’s diverse industries. Highlighting XLV's Key Holdings* The fund's composition showcases a selection of companies pivotal to healthcare’s wide-ranging facets: Eli Lilly (LLY) - 11.66% UnitedHealth (UNH) - 9.63% Johnson & Johnson (JNJ) - 6.90% AbbVie (ABBV) - 5.94% Merck (MRK) - 5.20% Thermo Fisher Scientific (TMO) - 4.25% Abbott Labs (ABT) - 3.35% Danaher (DHR) - 3.32% Amgen (AMGN) - 3.24% Pfizer (PFE) - 3.14% These holdings span pharmaceuticals, health insurance, medical devices, and diagnostics, illustrating the fund's encompassing approach to the healthcare sector. Sector Dynamics Influencing Healthcare Engagement The healthcare sector is characterized by factors such as demographic trends, technological advancements, and shifts in healthcare delivery models. These elements contribute to the sector's role within the broader economy and its relevance to consumer needs. Healthcare spending's share of Gross Domestic Product (GDP) has maintained a significant position, reflecting the sector's integral role in the economic landscape. This dynamic underscores the steady relevance of healthcare in consumer and governmental expenditure. The Strategic Appeal of the XLV Fund Investing in the Health Care Select Sector SPDR Fund (XLV) allows individuals to engage with the healthcare sector through a vehicle that offers balanced and diversified exposure. The fund's structure is designed to mitigate the risks associated with investing in individual companies by providing a portfolio that reflects the sector's breadth. For investors seeking a methodical approach to incorporating healthcare into their investment portfolios, XLV presents a tactful option. The fund's focus on core healthcare companies, coupled with its diversified strategy, affords a stable pathway to participation in the sector's activities. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 7/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007756 EXP 10/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

September 02, 2024 05:00 AM Eastern Daylight Time

1 ... 62 63 64 65 66 ... 3764